{
 "PrintNo":"S3272","Session":2019,"Chamber":"SENATE","BillType":"Senate","Published":"2019-02-05T10:43:01.051732Z",
 "Status":"IN_SENATE_COMM","Committee":"Insurance",
 "Milestones":[{"Type":"IN_SENATE_COMM","Date":"2020-01-08","Committee":"Insurance"}],
 "Actions":[
  {"Text":"REFERRED TO INSURANCE","Date":"2019-02-05","Chamber":"SENATE"},
  {"Text":"REFERRED TO INSURANCE","Date":"2020-01-08","Chamber":"SENATE"}
 ],
 "Sponsors":[{"ID":409,"Name":"Andrew J. Lanza","Short":"LANZA"}],
 "Title":"Limits the substitution of abuse-deterrent analgesic opioid drug products for analgesic opioids lacking such technology",
 "Summary":"Provides for patient access to FDA approved abuse-deterrent technology to help combat opioid abuse.",
 "LawSection":"Insurance Law","LawCode":"Add ยง3216-a, Ins L",
 "ActClause":"AN ACT to amend the insurance law, in relation to the use of abuse-deterrent technology for opioids as a mechanism for reducing abuse and diversion of opioid drugs",
 "PreviousVersions":["S6962-2015","S7009-2017"]
}